The recording of adverse events from psychological treatments in clinical trials: evidence from a review of NIHR-funded trials

被引:114
|
作者
Duggan, Conor [1 ,2 ]
Parry, Glenys [3 ]
McMurran, Mary [1 ]
Davidson, Kate [4 ]
Dennis, Jane [5 ]
机构
[1] Univ Nottingham, Inst Mental Hlth, Nottingham NG7 2TU, England
[2] Head Res & Dev, Borehamwood WD6 JN, Herts, England
[3] Univ Sheffield, Sch Hlth & Related Res, Ctr Psychol Serv Res, Sheffield S1 4DA, S Yorkshire, England
[4] Univ Glasgow, Gartnavel Royal Hosp, Coll Med Vet & Life Sci, Inst Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland
[5] Social Well Fare Grp, Bristol BS6 7DB, Avon, England
来源
TRIALS | 2014年 / 15卷
基金
美国国家卫生研究院;
关键词
Harm; Adverse events; Psychological interventions; Clinical trials; RANDOMIZED-TRIALS; PSYCHOTHERAPY; EXTENSION; THERAPY; SAFETY; HARMS;
D O I
10.1186/1745-6215-15-335
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: There is a concern in the literature that harm from interventions is insufficiently documented in clinical trials in general, and in those assessing psychological treatments in particular. A recent decision by a trial steering committee to stop recruitment into a randomized controlled trial (RCT) of a psychological intervention for personality disorder led to an investigation of the recording of harm in trials funded by the National Institute for Health Research (NIHR). Methods: The protocols and final reports of all 82 NIHR trials funded between 1995 and 2013 were examined for the reporting of adverse events. These were subdivided by category of intervention. Results: None of the psychological intervention trials mentioned the occurrence of an adverse event in their final report. Trials of drug treatments were more likely to mention adverse events in their protocols compared with those using psychological treatments. When adverse events were mentioned, the protocols of psychological interventions relied heavily on severe adverse events guidelines from the National Research Ethics Service (NRES), which were developed for drug rather than psychological interventions and so may not be appropriate for the latter. Conclusions: This survey supported the belief that the reporting of adverse events in psychological treatments is weak and the criteria used may not be appropriate. Recommendations are made as to how current practice might be improved.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Comparison of adverse events between oral and intravenous formulations of antimicrobial agents: a systematic review of the evidence from randomized trials
    Kouranos, Vasilios D.
    Karageorgopoulos, Drosos E.
    Peppas, George
    Falagas, Matthew E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (10) : 873 - 879
  • [22] Analysis of adverse events attribution and reporting in cancer clinical trials: A systematic review
    Enrico, Diego
    Waisberg, Federico
    Burton, Jeannette
    Mando, Pablo
    Chacon, Matias
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [23] Criteria to Report Adverse Drug Withdrawal Events in Clinical Trials: A Systematic Review
    Lee, Jimin J.
    Bortolussi-Courval, Emilie
    Filosa, Eva
    Rej, Soham
    Godard-Sebillote, Claire
    Tamblyn, Robyn
    Lee, Todd C.
    Mcdonald, Emily G.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2025,
  • [24] THE BENEFITS AND SAVINGS FROM PUBLICLY FUNDED CLINICAL TRIALS OF PRESCRIPTION DRUGS
    Baker, Dean
    INTERNATIONAL JOURNAL OF HEALTH SERVICES, 2008, 38 (04): : 731 - 750
  • [25] Sharing of Data From Industry-Funded Registered Clinical Trials
    Boutron, Isabelle
    Dechartres, Agnes
    Baron, Gabriel
    Li, Jacques
    Ravaud, Philippe
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (24): : 2729 - 2730
  • [26] Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials
    Brache, V
    Faundes, A
    Alvarez, F
    Cochon, L
    CONTRACEPTION, 2002, 65 (01) : 63 - 74
  • [27] Treatment of hypertension and the price to pay; adverse events and discontinuation from randomized treatment in clinical trials
    Kjeldsen, Sverre E.
    Os, Ingrid
    Redon, Josep
    JOURNAL OF HYPERTENSION, 2016, 34 (08) : 1489 - 1491
  • [28] Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal
    Crepin, Sabrina
    Villeneuve, Claire
    Merle, Louis
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (06) : 719 - 724
  • [29] Psychiatric adverse events from the DTG ART-naive phase 3 clinical trials
    Quercia, Romina
    Roberts, Jeremy
    Murungi, Andrew
    Curtis, Lloyd
    Payvandy, Nassrin
    Koteff, Justin
    Aboud, Michael
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [30] Representation and Extrapolation: Evidence from Clinical Trials
    Alsan, Marcella
    Durvasula, Maya
    Gupta, Harsh
    Schwartzstein, Joshua
    Williams, Heidi
    QUARTERLY JOURNAL OF ECONOMICS, 2024, 139 (01): : 575 - 635